ERBB2 and colorectal carcinoma: DESTINY-CRC01 (DCRC01) trial of T-DXd in CRC patients reported that higher levels of HER2 biomarkers in baseline tissue and liquid biopsies, including HER2 status (IHC/ISH), HER2/CEP17 ratio, HER2 ISH signals, HER2 H-score, plasma HER2 [Human Epidermal Growth Factor Receptor 2 (ERBB2)] amplification status, HER2-adjusted plasma copy number, and HER2 extracellular domain correlate with antitumor activity (24).